Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia | Zendy

Roberto Latagliata | Zendy; Alessandro Isidori | Zendy; Massimo Breccia | Zendy; Ida Carmosino | Zendy; Federico Vozella | Zendy; Paola Volpicelli | Zendy; Paola Finsinger | Zendy; Sara Barulli | Zendy; Giuseppina Loglisci | Zendy; Michelina Santopietro | Zendy; Vincenzo Federico | Zendy; D. Diverio | Zendy; Mauro Nanni | Zendy; Marco Mancini | Zendy; Giuseppe Visani | Zendy; Giuliana Alimena | Zendy

Open Access

Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia

Author(s) -

Roberto Latagliata,

Alessandro Isidori,

Massimo Breccia,

Ida Carmosino,

Federico Vozella,

Paola Volpicelli,

Paola Finsinger,

Sara Barulli,

Giuseppina Loglisci,

Michelina Santopietro,

Vincenzo Federico,

D. Diverio,

Mauro Nanni,

Marco Mancini,

Giuseppe Visani,

Giuliana Alimena

Publication year - 2012

Publication title -

acta haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.574

H-Index - 56

eISSN - 1421-9662

pISSN - 0001-5792

DOI - 10.1159/000343384

Subject(s) - medicine , chronic myelogenous leukemia , imatinib , incidence (geometry) , imatinib mesylate , gastroenterology , surgery , univariate analysis , leukemia , multivariate analysis , physics , myeloid leukemia , optics

To address the incidence and the prognostic role of a very early standard complete cytogenetic response (CCyR) or all Ph- metaphases (MET-, when <20 cells were evaluable).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research